Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.245 +0.085 (+3.94%)
Streaming Delayed Price Updated: 3:37 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. 
Via The Motley Fool
Cassava Sciences Stock Looks Ready To Break Out If This Pattern Is Confirmed
Cassava Sciences Inc. (NASDAQ: SAVA) shares were moving Monday after the company announced positive clinical data with SavaDx. SavaDx is an investigational diagnostic to... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
This morning 121 companies reached new 52-week highs. Areas of Significance: Alphabet (NASDAQ:GOOGL) was the largest company by market cap to set a new 52-week high... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Don't Get Faked Out By The Fear & Greed Index
False positives can prevent gains. Consider another approach. 
Via Talk Markets
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer’s Results
Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have. 
Via InvestorPlace
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments
Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment. Two Stocks Spike On Alzheimer... 
Via Benzinga
Update On A Bear-Proof Portfolio: The Portfolio We Presented Earlier This Week Is Off To A Fast Start
Japanese gameshow contestant versus bear. Image via TMZ. Bear-Proof Portfolio Update Here's the "bear-proof" portfolio we presented in our pre-market post on... 
Via Benzinga
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell. 
Via Investor's Business Daily
An Unforgettable Week For Alzheimer's Treatment Stocks
Two of our recent top stocks spiked on news of potentially promising Alzheimer's treatments this week. They're both risky names, so we look at how to hold them without losing your shirt. 
Via Talk Markets
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14,... 
Via Benzinga
Update On A Bear-Proof Portfolio
A quick update on the portfolio we presented here in our pre-market post on Tuesday. 
Via Talk Markets
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
2 High-Risk, High-Reward Stocks That Could Go to the Moon
Risk-averse investors may want to look elsewhere. 
Via The Motley Fool
61 Biggest Movers From Yesterday
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's... 
Via Benzinga
Here's Why Cassava Sciences Is Surging Today
Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference. 
Via The Motley Fool
SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars
SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3... 
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to... 
Via Benzinga
Building A Bear-Proof Portfolio: Investing Safely Up As The Fear & Greed Index Approaches Early 2020 Levels.
Market Fear Gauge Approaches 2020 Levels As ZeroHedge reported on Monday, the Fear & Greed gauge has approached early 2020 levels. Screen capture via... 
Via Benzinga
Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021
This small-cap biotech has shot up in value as the company's Alzheimer's drug makes it way through clinical trials. 
Via The Motley Fool
Is Now The Time To Buy Stock In Cassava Sciences, Facebook Or Apple?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Why Is Cassava Sciences Stock Soaring in 2021?
The stock market is excited by the clinical trial results for its Alzheimer's drug. 
Via The Motley Fool
10 Biggest Price Target Changes For Tuesday
Citigroup boosted International Business Machines Corporation (NYSE: 
Via Benzinga
Building A Bear-Proof Portfolio
How to invest confidently as the Fear & Greed gauge hits early 2020 fear levels. 
Via Talk Markets
Understanding Cassava Sciences's Unusual Options Activity
Cassava Sciences (NASDAQ:SAVA) shares experienced unusual options activity on Friday. The stock price moved down to $79.73 following the option alert. Sentiment: BEARISH Option... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Sight Sciences, Inc. (NASDAQ: SGHT) shares jumped 39.6% to settle at $33.50 on Thursday as the company priced its IPO at $24 per share. Cinedigm Corp. (NASDAQ: CIDM)... 
Via Benzinga
Topics Initial Public Offering
Why Cassava Sciences Stock Moved Higher Monday
The biotech stock bounced back big Monday after tumbling on Friday. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.